Sirtex Medical has unveiled its new SIR-Spheres® FLEXdose SELECT Delivery Program, designed to enhance Y-90 selective internal radiation therapy for metastatic colorectal cancer.

This innovative program features a flexible, patient-specific dosing approach with a single 3mL delivery vial, compared to the traditional 5mL vials.

The new 3mL vials contain approximately 27 million microspheres, offering a more tailored treatment option.

The FLEXdose SELECT program provides up to five days of pre-calibration, available daily, facilitating precise Y-90 therapy.

Matt Schmidt, CEO of Sirtex Medical Limited, emphasized that this advancement aims to meet the needs of patients and healthcare providers by enabling personalized doses and faster treatment delivery.

The Miami Cardiac & Vascular Institute and Miami Cancer Institute endorsed the program, praising its ability to deliver timely and customized treatments. Commended Sirtex for expanding treatment options and improving strategies for patient care.





Source: sirtex.com

Report Abuse